Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H1 2018

Publisher Name :
Date: 18-Jan-2018
No. of pages: 82
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H1 2018, provides an overview of the Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) (Gastrointestinal) pipeline landscape.

Atypical hemolytic uremic syndrome is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. Symptoms include vomiting, abdominal pain, pale skin tone, fatigue and irritability, blood in the urine and confusion.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 3 and 2 respectively.

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) (Gastrointestinal).

  • The pipeline guide reviews pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) (Gastrointestinal) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) (Gastrointestinal).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H1 2018

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Overview
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Companies Involved in Therapeutics Development
Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
ChemoCentryx Inc
greenovation Biotech GmbH
Omeros Corp
Ra Pharmaceuticals Inc
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Drug Profiles
ACH-4471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cemdisiran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Coversin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRN-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-721 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RA-101495 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ravulizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Dormant Projects
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Product Development Milestones
Featured News & Press Releases
Jan 08, 2018: Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment
Jan 03, 2018: Omeros Reaches Agreement with FDA on OMS721 Phase 3 Trial Protocol for IgA Nephropathy
Oct 16, 2017: Omeros Announces Upcoming Presentation of Clinical OMS721 Data at European Society for Blood and Marrow Transplantation
Sep 26, 2017: Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS)
Mar 27, 2017: Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology
Oct 27, 2016: Alexion Initiates Simultaneous Registration Trials of ALXN1210 for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016
Sep 06, 2016: Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop
Jul 28, 2016: Omeros Confirms OMS721 Phase 3 Development Plan with European Medicines Agency
May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress
Mar 08, 2016: Omeros Initiates its Phase 3 Program for OMS721 in aHUS Following Meeting with FDA
Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial
Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays
Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting
Dec 05, 2015: Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Achillion Pharmaceuticals Inc, H1 2018
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Akari Therapeutics Plc, H1 2018
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H1 2018
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Alnylam Pharmaceuticals Inc, H1 2018
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Amgen Inc, H1 2018
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by ChemoCentryx Inc, H1 2018
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by greenovation Biotech GmbH, H1 2018
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Omeros Corp, H1 2018
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Ra Pharmaceuticals Inc, H1 2018
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Infantile Spasms Therapeutics Market Insights, Forecast to 2025
    Published: 20-Mar-2019        Price: US 3900 Onwards        Pages: 117
    An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with s......
  • Global Enzyme Replacement Therapy Market Size, Status and Forecast 2019-2025
    Published: 20-Mar-2019        Price: US 3900 Onwards        Pages: 90
    Enzyme replacement therapy (ERT) is a medical treatment which replaces an enzyme that is deficient or absent in the body. Usually, this is done by giving the patient an intravenous (IV) infusion of a solution containing the enzyme. The classification of enzyme replacement therapy includes injectable agents and oral agents, and the revenue proportion of injectable agents in 2017 is about 62.38%, and the proportion is in increasing trend from 2013 to 2017. North America is the larges......
  • Global Body Contouring Implants Market Size, Status and Forecast 2019-2025
    Published: 15-Mar-2019        Price: US 3900 Onwards        Pages: 90
    The body contouring implant range includes silicone gel implants for the calves, glutes and the male chest. In 2018, the global Body Contouring Implants market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Body Contouring Implants status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Body Contouring Implan......
  • Global Enzyme Replacement Therapy Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    Published: 15-Mar-2019        Price: US 3480 Onwards        Pages: 119
    Enzyme replacement therapy (ERT) is a medical treatment which replaces an enzyme that is deficient or absent in the body. Usually, this is done by giving the patient an intravenous (IV) infusion of a solution containing the enzyme. Scope of the Report: The classification of enzyme replacement therapy includes injectable agents and oral agents, and the revenue proportion of injectable agents in 2017 is about 62.38%, and the proportion is in increasing trend from 2013 to 2017......
  • Global Substance Abuse Treatment Market Data Survey Report 2013-2025
    Published: 15-Mar-2019        Price: US 1500 Onwards        Pages: 61
    Summary The global Substance Abuse Treatment market will reach xxx Million USD in 2019 with CAGR xx% 2019-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers profile, products & services, sales data of business Global market size by Major Application Global market size by Major Type Key manufacturers are included based on compan......
  • Brachytherapy afterloaders, Brachytherapy seeds Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 14-Mar-2019        Price: US 3000 Onwards        Pages: 136
    Brachytherapy Afterloaders, Brachytherapy Seeds Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Brachytherapy Afterloaders, Brachytherapy Seeds industry with a focus on the Chinese market. The report provides key statistics on the market status of the Brachytherapy Afterloaders, Brachytherapy Seeds manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Ove......
  • Global Varicose Vein Treatment Market Research Report 2019
    Published: 14-Mar-2019        Price: US 2900 Onwards        Pages: 98
    Varicose Veins also referred to as varicosities are swollen, blue, twisted veins that appear on the skin. These are often seen near the legs. The global Varicose Vein Treatment market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. This report focuses on Varicose Vein Treatment volume and value at global level, regional level and company level. From a global perspective, this report repr......
  • Tissue expanders Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 13-Mar-2019        Price: US 3000 Onwards        Pages: 144
    Tissue Expanders Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Tissue Expanders industry with a focus on the Chinese market. The report provides key statistics on the market status of the Tissue Expanders manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese Tissue Expander......
  • Global Thyroid Gland Disorders Treatment Industry Research Report Growth Trends and Competitive Analysis 2019-2025
    Published: 11-Mar-2019        Price: US 4900 Onwards        Pages: 168
    In the last several years, global market of Thyroid Gland Disorders Treatment developed stable, with an average growth rate of 4.53% during 2013 to 2018. In 2018, global revenue of Thyroid Gland Disorders Treatment is nearly 2.74 Billion USD. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis. T......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs